bimagrumab glp-1 Obesity research is moving beyond how much weight we lose to what kind of weight we lose Beyond GLP-1s: The Next Obesity

These somatotrophs constitute approximately 50% of the anterior pituitary cell population and are specialized for synthesis and secretion of growth hormone (GH, also called somatotropin), a 191-amino acid peptide hormone that is one of the most important regulators of growth, metabolism, and body composition

The rates are remarkably similar across all three, despite their different mechanisms: Semaglutide: Nausea approximately 18%, diarrhea approximately 12%, vomiting approximately 8% Tirzepatide: Nausea 17-22% (dose dependent), diarrhea 13-16%, vomiting 6-10% Retatrutide: Nausea 16-25% (dose dependent), diarrhea 15-22%, vomiting 8-13% The pattern holds consistently

In a real-world study summarizing data collected from five European countries plus Canada in 20152016, between 4 and 24% of patients had switched treatments at 1 year after their first GLP-1 RA prescription [10]

Murray M.Fisher

ingredient transparency is limited

The MRI also tells me if the tear is from gradual wear over time (degenerative), which is common in older patients and usually responds well to non-surgical care